case_images: PMC11775475_01
case_images: The patient's entire treatment and monitoring process from oxaliplatin exposure to post-treatment with tocilizumab. In the first three cycles of immunochemotherapy, toripalimab 240 mg was infused on day 0, followed by gemcitabine 1800 mg, oxaliplatin 170 mg, and pegaspargase 3750 IU on day 1. During the fourth cycle, toripalimab was administered on day 0, and gemcitabine was infused successfully on day 1. However, after approximately 50 mg of oxaliplatin, the patient developed hypersensitivity symptoms and elevated IL-6 levels (>5,000 pg/mL). Conventional treatments failed to alleviate symptoms, including fever and dyspnea. On day 2, following tocilizumab infusion, IL-6 levels decreased to 86.8 pg/mL, and the patient's symptoms improved. On day 4, pegaspargase 3750 IU was administered, and the patient was discharged on day 5. One month later, PET-CT showed complete tumor remission. In the fifth cycle, the patient received toripalimab, gemcitabine, and pegaspargase, followed by toripalimab for maintenance therapy for 1 year.
case_images: fphar-15-1471038-g001.jpg
case_images: PMC11775475_01_fphar-15-1471038-g001.jpg
case_images: F1
case_images: The patient's entire treatment and monitoring process from exposure to oxaliplatin to post-treatment with tocilizumab is shown in Figure 1.